Enliven Therapeutics, Inc. (NASDAQ:ELVN) Position Increased by State Street Corp

State Street Corp lifted its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 2.9% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 745,944 shares of the company’s stock after buying an additional 21,018 shares during the quarter. State Street Corp owned approximately 1.58% of Enliven Therapeutics worth $19,051,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of ELVN. Quest Partners LLC lifted its holdings in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after purchasing an additional 3,559 shares during the period. SG Americas Securities LLC bought a new position in Enliven Therapeutics during the 3rd quarter worth $256,000. Verition Fund Management LLC acquired a new stake in Enliven Therapeutics in the third quarter worth $271,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Enliven Therapeutics in the second quarter valued at $322,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Trading Up 4.3 %

Enliven Therapeutics stock opened at $23.43 on Tuesday. Enliven Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $30.03. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -12.33 and a beta of 1.02. The company’s 50-day moving average price is $26.02 and its two-hundred day moving average price is $24.26.

Insider Activity

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 4,250 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $24.27, for a total value of $103,147.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Joseph P. Lyssikatos sold 7,522 shares of the company’s stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $27.51, for a total transaction of $206,930.22. Following the completion of the sale, the insider now directly owns 1,069,887 shares of the company’s stock, valued at $29,432,591.37. The trade was a 0.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 129,195 shares of company stock worth $3,581,772 over the last three months. Corporate insiders own 29.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ELVN. BTIG Research started coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Finally, Robert W. Baird boosted their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $38.25.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.